Chemical, Structural, Clinical and Biological details of Antiviral agents ID: DrugRepV_1677



Chemical Information
Antiviral agent IDDrugRepV_1677
Antiviral agent namePhenazopyridine Hydrochloride Drug Bank
IUPAC Name3-phenyldiazenylpyridine-2,6-diamine;hydrochloride PubChem
SMILES (canonical)C1=CC=C(C=C1)N=NC2=C(N=C(C=C2)N)N.Cl PubChem
Molecular FormulaC11H12ClN5 PubChem
Molecular Weight (g/mol)249.702 PubChem
InChlInChI=1S/C11H11N5.ClH/c12-10-7-6-9(11(13)14-10)16-15-8-4-2-1-3-5-8;/h1-7H,(H4,12,13,14);1H PubChem
Common NamePhenazopyridine HCl Drug Bank
Synonyms3-Phenylazo-2,6-diaminopyridine hydrochloride | Phenazopyridinium chloride | 3-Phenylazo-2,6-diaminopyridine Monohydrochloride | 2,6-Diamino-3-(phenylazo)pyridine monohydrochloride | Phenylazodiaminopyridine hydrochloride | Phenylazo-alpha,alpha'-diaminopyridine monohydrochloride
Structural Information
  
Clinical Information
CategoryGenito Urinary System and Sex Hormones
Primary Indication (Clinical trial phases)Approved Drug Bank
Biological Information
Primary Indication (Disease Category) Non Infectious Disease
Primary Indication (Disease)Urinary tract infection
Secondary Indication Zika virus (ZIKV) NA MR766World Health OrganisationCDC
Secondary Indication (Approaches)Experimental-HTS
Secondary Indication (Methods)In-vitro
Secondary Indication (Model system) [cell lines/ animal models]Astrocytes
Secondary Indication (Mode of viral infection)Adsorption
Secondary Indication (Viral titer)1 MOI
Secondary Indication (Mode of drug delivery) Culture
Secondary Indication (Cell based assay)Cell viability assay
Secondary Indication (Change)No significant effect
Secondary Indication (Type of Inhibition) Percentage Inhibition [ 0 % ]
ReferenceXu M, Lee EM, Wen Z, Cheng Y, Huang WK, Qian X, Tcw J, Kouznetsova J, Ogden SC, Hammack C, Jacob F,.Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen.Nat Med. 2016 Oct;22(10):1101-1107. doi: 10.1038/nm.4184. Epub 2016 Aug 29. PMID:27571349 PubMed
CommentThe identified compounds that either inhibit ZIKV infection or suppress infection-induced caspase-3 activity in different neural cells